Cochrane News

Preterm birth delay drugs safe for global reduction in neonatal death

9 months 3 weeks ago

Women around the world should be able to access the best medical treatments that help to delay preterm births and improve neonatal outcomes, updated Cochrane network meta-analysis suggests.

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm, and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information.

A new Cochrane Pregnancy and Childbirth paper published in the Cochrane Library looked at data from 122 clinical trials to create a league table of drugs that delay birth, called tocolytics, about their effectiveness and side effects. Researchers from the University of Birmingham and World Health Organization reviewed 122 randomised trials, published between 1966 and 2021, involving 13,697 women and conducted in 39 countries including high, middle and low-income states.

Women benefitted from all preterm delay treatments included in the meta-analysis of studies, although the research team noted that the effectiveness of different drugs was less clear in some of the studies considered. The team also looked at the side effects of different drugs and combinations, including the likelihood of having to stop treatment.

The team have bought together the evidence on the benefits as well as the harms of these treatments (compared to no treatment or placebo), to arm clinicians and policy makers around the world with the information to decide upon the best treatment for the women in their care in their specific setting.

Dr Amie Wilson, Research Fellow Global Maternal Health at the University of Birmingham said:

The findings show that the benefits of these drugs outweigh any risks associated with unwanted side effects. These treatments are leading to a significant reduction in the number of deadly preterm births, and we now need to further understand the effectiveness of tocolytics for specific groups depending on pregnancy length.

Our previous research has led to the improvement of guidelines for use of tocolysis drug use to delay preterm birth in the UK. Knowing that this paper helped to inform the forthcoming recommendations of the World Health Organization on the use of tocolytics, we hope that many more women around the globe will have access to these drugs, and have healthier births.

Dr Victoria Hodgetts Morton, NIHR Clinical Lecturer in Obstetrics at the University of Birmingham and co-author of the paper said:

Preterm birth is the most common reason why a newborn baby may die, and the leading cause of death in children under five years of age.

Tocolytics aim to delay preterm birth and allow time for the women to receive medicines that can help with baby's breathing and feeding if born preterm, and medicines that lower the chance of cerebral palsy of the infant. Crucially, a short delay in preterm birth can enable women to reach specialist care.

Full citation: Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database of Systematic Reviews 2022, Issue 8. Art. No.: CD014978. DOI: 10.1002/14651858.CD014978.pub2

Thursday, September 8, 2022
Muriah Umoquit

Special Collection: Achieving sustainable healthcare through deprescribing of unnecessary medications

10 months 2 weeks ago

 A new Cochrane Library Special Collection provides an overview of Cochrane Reviews that summarize the potential benefits and harms of deprescribing specific medications and help to inform how to implement deprescribing across different settings and populations.

This collection of reviews highlight that deprescribing is likely feasible and safe and can lead to benefits in prescribing and clinical outcomes. However, they also highlight significant gaps in the literature and methodological challenges to both conducting deprescribing studies and systematic reviews of deprescribing.

Wednesday, July 20, 2022
Muriah Umoquit

This week Catherine Spencer starts as Cochrane’s new Chief Executive Officer

10 months 3 weeks ago

Catherine joins Cochrane from The Seafarers’ Charity where she held the position of CEO.

Governing Board Co-Chairs, Tracey Howe and Catherine Marshall said: "We are delighted to welcome Catherine to Cochrane. Catherine is a proven Chief Executive with an exceptional record leading non-profit organisations. She brings expertise in strategic planning, change management, and communications under pinned by a global perspective. Catherine is well positioned to partner with the Editor-in-Chief, Karla Soares-Weiser, to lead Cochrane as we drive an exciting programme of delivering trusted evidence, promoting informed decisions, and better health.”

Prior to her role at The Seafarers’ Charity, Catherine was acting Chief Operating Officer and Director of Communications and Change Management at international public health research organisation, icddrb, in Dhaka, Bangladesh. Between 2008-2015 Catherine held various senior management roles at the Army Families Federation, including three years as Chief Executive.

Catherine Spencer said, “Like all organisations post-Covid, we have challenges to deal with, but I see so much opportunity for Cochrane in the future. I look forward to what will inevitably be stimulating conversations with the Cochrane Community about what a thriving future Cochrane looks like and what we need to do to achieve that as we build a long-term strategy together.

I spent three and a half years working at icddr,b, in Dhaka, Bangladesh - a large public health research organisation, that at the time was facing enormous financial and structural challenge. Working as part of the Senior Leadership Team, and very closely with the Executive Director and Board, the organization was rejuvenated, meaning its essential public health research could continue. Thus, I come to Cochrane familiar with an organisation managing change and I look forward to working with you, collaboratively to steer Cochrane to success.”

Catherine will meet with the Cochrane Community in two introductory webinars to accommodate different time zones. Invites will be sent directly to Community Members via email.


Tuesday, July 12, 2022
Muriah Umoquit

Cochrane seeks Managing Editor

11 months 1 week ago

Specifications: Full Time (Permanent)
Salary: circa £40,000 per annum
Location: Ideally based in the UK, Germany or Denmark. Candidates from the rest of the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries (1-year fixed-term contracts)
Application Closing Date: 7th September 2022


Cochrane has established a centrally-resourced Editorial Service to support the efficient and timely publication of high-quality systematic reviews in the Cochrane Library. The reviews that are published through the Central Editorial Service address some of the research questions considered to be the most important to decision makers.

Reporting to the Executive Editor of the Central Editorial Service, the Managing Editor will manage the editorial process of protocols and reviews submitted to the Central Editorial Service. The role-holder should be alert to the demands of delivering high-quality review content for publication in a timely fashion, and work to ensure that deadlines can be met.   

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information. An understanding of Cochrane’s work and health research more generally is an advantage, but not essential.

The majority of Cochrane Central Executive staff are located in London, UK, however flexible locations are possible for the right candidate. Please note, however, that we are only able to offer consultancy contracts outside of the UK, Germany or Denmark.

We will consider extended notice periods if required for applicants who wish to honour existing contracts. We fully support remote and flexible working arrangements. 

How to apply

  • For further information on the role and how to apply, please click here
  • The deadline to receive your application is by 7th September. 
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Read our Recruitment Privacy Statement
Thursday, August 18, 2022 Category: Jobs
Lydia Parsonson

Cochrane seeks Methods Implementation Editor

11 months 1 week ago

Specifications: Permanent
Salary: £45,000 per annum
Location: UK
Application Closing Date:  17 July 2022

To provide strategic support to deliver cross-departmental objectives and targets by:

  • Working closely with the Editorial Product Lead and the methods community to deliver on activities so Cochrane can produce and publish a variety of evidence synthesis types and other content that align with Cochrane’s strategy for review production and meet Cochrane’s mission.
  • Coordinating the development of best practice resources for Cochrane’s methodological standards.
  • Leading on editorial and methods projects to develop Cochrane’s platforms and processes.
  • Being the main point of contact for the methods community and engaging with Methods Groups, the Methods Executive and Methods Network to facilitate their involvement with Cochrane.

The Methods Implementation Editor will provide strategic editorial and methods support to departments across Cochrane and the methods community to enable efficient, high-quality review production for a variety of types of evidence syntheses and methods. Overall, this role will contribute to streamlining and simplifying review production and publication to support Cochrane’s efficiency and sustainability as an organisation.

How to apply

  • For further information on the role and how to apply, please click here.
  • The deadline to receive your application is by 17 July 2022.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Read our Recruitment Privacy Statement


Tuesday, June 28, 2022 Category: Jobs
Lydia Parsonson

Free Webinar: From Evidence of Overuse to De-implementation

11 months 1 week ago

Cochrane Sustainable Healthcare and Choosing Wisely Canada invite you to join a free live webinar where leading experts discuss the challenges of abandoning existing low-value care practices, which may not be beneficial or even cause harm to patients. Ideal for healthcare professionals, guideline developers, and policy makers.

Experts will share experiences on how to address the urgency of finding out when and how de-implementation, de-intensification of medical interventions, and diagnostics should be undertaken, without causing harm to patients, de-professionalizing clinicians, or counteracting shared decision-making processes.

 10 Oct 2022
4:00pm - 5:30pm CET (View in your time zone) 
View agenda
Register for free



Tuesday, October 4, 2022
Muriah Umoquit

Cochrane seeks Internal Communications Executive

11 months 1 week ago

Specifications: 12 months Fixed term/Consultancy contract dependant on location
Salary: £42,000 per annum
Location: Flexible
Application Closing Date:  12 August 2022

Cochrane requires a talented internal communications specialist to contribute to the development and implementation of a complex, organization-wide transformation and change management programme to be rolled out over the next 12 months. The key focus of this varied role will be creating and delivering a strategic internal communications plan to support our ongoing transformation programmes. This will involve creating and disseminating clear, informative and engaging content (including online news and social media posts, videos and e-newsletters) for the Cochrane community and the many diverse audiences within it.

Cochrane manages a large number of websites and social media channels. The organisation also uses a digital marketing database for targeted mailings and newsletters; and can segment audiences to ensure effective communication.

This role would suit an individual who embraces change; whilst understanding how to convey key messages to stakeholder groups impacted by this change.

Cochrane is a global network of more than 115,000 people, and our internal community accounts for around 1,000 of those people. This role will need to work effectively across the internal community network, demonstrating excellent cross-cultural working. 

How to apply

  • For further information on the role and how to apply, please click here
  • The deadline to receive your application is by 12 August 2022. 
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Read our Recruitment Privacy Statement 
Monday, August 1, 2022 Category: Jobs
Lydia Parsonson

Ivermectin for preventing and treating COVID-19

11 months 2 weeks ago

Is ivermectin effective for COVID‐19? Updated Cochrane review 'Ivermectin for preventing and treating COVID‐19'

Key messages

  • We found no evidence to support the use of ivermectin for treating COVID‐19 or preventing SARS‐CoV‐2 infection. The evidence base improved slightly in this update, but is still limited.
  • Evaluation of ivermectin is continuing in 31 ongoing trials, and we will update this review again when their results become available.  

What is ivermectin?
Ivermectin is a medicine used to treat parasites, such as intestinal parasites in animals, and scabies in humans. It is inexpensive and is widely used in regions of the world where parasitic infestations are common. It has few unwanted effects.  

Medical regulators have not approved ivermectin for COVID‐19.

What did we want to find out?
We wanted to update our knowledge of whether ivermectin reduces death, illness, and length of infection in people with COVID‐19, or is useful in prevention of the infection. We included trials comparing the medicine to placebo (dummy treatment), usual care, or treatments for COVID‐19 that are known to work to some extent, such as dexamethasone. We excluded trials comparing ivermectin to other medicines that do not work, like hydroxychloroquine, or whose effectiveness against COVID‐19 is uncertain.

We evaluated the effects of ivermectin in infected people on:

  • people dying;
  • whether people's COVID‐19 got better or worse;
  • quality of life;
  • serious and non‐serious unwanted effects;
  • viral clearance.

For prevention, we sought the effect on preventing SARS‐CoV‐2 infection and COVID‐19 disease.

What did we do?
We searched for randomized controlled trials that investigated ivermectin to prevent or treat COVID‐19. People treated in hospital or as outpatients had to have laboratory‐confirmed COVID‐19.

In this update, we also investigated the trustworthiness of the trials and only included them if they fulfilled clear ethical and scientific criteria.

We compared and summarized the results of the trials and rated our confidence in the evidence, based on common criteria such as trial methods and sizes.

What did we find?
We excluded seven of the 14 trials included in the previous review as these trials did not fulfil the expected ethical and scientific criteria. Together with four new trials, we included 11 trials with 3409 participants that investigated ivermectin combined with any usual care compared to the same usual care or placebo.

For treatment, there were five trials of people in hospital with moderate COVID‐19 and six trials of outpatients with mild COVID‐19. The trials used different doses of ivermectin and different durations of treatment.  

No trial investigated ivermectin to prevent SARS‐CoV‐2 infection.

We also found 31 ongoing trials, and an additional 28 trials still requiring clarification from the authors or not yet published.

Main results  

Treating people in hospital with COVID‐19

We do not know whether ivermectin compared with placebo or usual care 28 days after treatment:

  • leads to more or fewer deaths (3 trials, 230 people);
  • worsens or improves patients' condition, assessed by need for ventilation or death (2 trials, 118 people);
  • increases or reduces serious unwanted events (2 trials, 197 people).

Ivermectin compared with placebo or usual care 28 days after treatment, may make little or no difference to:

  • improving patients' condition, assessed by discharge from hospital (1 trial, 73 people);
  • non‐serious unwanted events (3 trials, 228 participants). 

Seven days after treatment, ivermectin may make little or no difference to reduction of negative COVID‐19 tests (3 trials, 231 participants) compared with placebo or usual care.

Treating outpatients with COVID‐19
Ivermectin compared with placebo or usual care 28 days after treatment, probably makes little or no difference to people dying (6 trials, 2860 people).

Ivermectin compared with placebo or usual care 28 days after treatment, makes little or no difference to quality of life (1 trial, 1358 people).

Ivermectin compared with placebo or usual care 28 days after treatment, may make little or no difference to:

  • worsening patients' condition, assessed by admission to hospital or death (2 trials, 590 people);
  • serious unwanted events (5 trials, 1502 people);
  • non‐serious unwanted events (5 trials, 1502 participants);
  • improving people's COVID‐19 symptoms in the 14 days after treatment (2 trials, 478 people);
  • number of people with negative COVID‐19 tests 7 days after treatment (2 trials, 331 people).

Review authors, Dr Maria Popp and Dr Stephanie Weibel said:

“Overall, the outlook for ivermectin’s use to treat or prevent SARS-CoV-2 is poor. While laboratory results showed some promise, real-life outcomes suggest no or very little impact on mortality rates, illness, and length of infection.”

What are the limitations of the evidence?
Our confidence in the evidence, especially for outpatients, improved since the last review version, because we could look at more participants included in high‐quality trials. Although we are quite certain regarding our results on risk of people dying and quality of life, the confidence in the evidence is still low for many other outpatient and inpatient outcomes because there were only few events measured. The methods differed between trials, and they did not report everything we were interested in, such as relevant outcomes.

How up to date is this evidence?
The systematic literature search is up to date to 16 December 2021. Additionally, we included trials with > 1000 participants up to April 2022.


Wednesday, June 22, 2022
Katie Abbotts

Cochrane Rapid Reviews Methods Group seeks graduate research assistant - Flexible location

11 months 2 weeks ago

Specifications: 20 hours/week until 31 December, 2022
Salary: £1,500 per month
Location: Flexible Location, Remote Work
Application Closing Date:  3 July, 2022

The Cochrane Rapid Reviews Methods Group is currently looking for a Graduate Research Assistant with experience in rapid or systematic reviews for 20 hours/week (temporary position until December 31, 2022).

Required qualifications:

  • Graduate or PhD student in the field of health care (medicine, public health, biology, psychology, nursing science etc.)
  • Good understanding of rapid reviews
  • Experience in conducting systematic reviews
  • Excellent writing skills in English (C1)


  • Support the Cochrane Rapid Reviews Methods Group (CRRMG) in providing rapid review guidance for the Cochrane Handbook, the Rapid Review Methods Guidance, and journal publications
  • Support the CRRMG with scheduling and preparing workshops
  • Communicate and collaborate with various other groups at Cochrane (e.g., editorial team)


  • Flexible working hours
  • 100% remote working possible

The successful candidate will be hired by Cochrane Austria at the University for Continuing Education Krems, Austria. The salary will be 1500 EUR per month. All applications must be submitted by Sunday, July 3, 2022 per email at

Please include: 

  • Curriculum vitae
  • Cover letter
  • Certificates

If you have any questions, please contact Sandra Hummel (

We look forward to hearing from you! 

Monday, June 20, 2022 Category: Jobs
Muriah Umoquit

How to talk about vaccines when you’re not an expert: a Lifeology and Cochrane collaboration

11 months 2 weeks ago

In this free course, learn how you can talk about vaccines with anyone!

Just because you’re a researcher, clinician, or  scientist doesn't mean that you should know everything about viruses and vaccines…but you may be asked to talk about them! It's important to remember that these conversations aren’t just about facts and information. They can be an opportunity to build trust and advocate for science! ‘How to talk about vaccines when you’re not an expert’ is a free Lifeology course that walks you through practical tips that you can apply next time you’re asked about the topic.

Lifeology’s tagline is ‘The place where science and art converge’. They offer a platform that brings together scientists, artists, and storytellers to help people better understand and engage with science, health information, and research. One of the main ways they meet their objectives is through beautifully illustrated, evidence-informed, bite-sized ‘flashcard’ courses about science and health-related topics aimed at the general public and students. There have been other collaborations with Cochrane on courses, including ‘What is an infodemic and how can we prevent it?’ and 'How to communication scientific uncertainty.'


“This course was inspired by real events – and one many can relate to!” explains author Muriah Umoquit, Cochrane’s Communications and Engagement Officer. “I baked 7 dozen cookies and found myself at a cookie exchange…where everyone was against the COVID-19 vaccine. As a professional health communicator, I felt like I should educate them with the latest studies and dazzle them into being pro-science over our appetizers! But instead, I froze. And when the subject changed, I left. It was a missed opportunity and one that many researchers and scientists find themselves in. This course gives practical advice to draw from, so we can all be more confident in our conversations about vaccines or other health or science conversations.”

The course has  22 cards that share the story of a systematic reviewer asking their colleague for advice when talking about vaccines. It features the art of Abbey Morris. “When creating the illustrations, I made a conscious effort to use inclusive imagery and avoided adding any text that would hinder future language translations,” Abby explains. “I also hope the Cochrane Community will enjoy some  hidden ‘Easter Eggs’ in this course just for them!”

Ruobing Li researches vaccine hesitancy at the Alan Alda Centre for Communicating Science and also collaborated on this project with us by  reviewing the content. “Sharing science is not just about sharing facts and information. This course is short, practical in its advice, and really accessible. Trust in science isn’t built in one conversation; I hope this course will encourage and give confidence to all scientists and researchers to have many conversations!”

Having a course that would be assessable in multiple languages was also built into its design. Juan Franco, Cochrane Board Member, family physician, researcher, and Editor-in-Chief of Evidence-Based Medicine was another reviewer of this course. "Muriah and her colleagues designed this course knowing that we wanted to make it assessable to a global audience through our amazing Cochrane Translation Teams" Juan explains. "For this reason, we provided feedback to be sure to avoid words in the illustrations, cultural-specific analogies or phrases, and complex words. The end result makes for a great course in any language!"

View the Lifeology course ‘How to talk about vaccines when you’re not an expert' in:

Learn more about Lifeology: 

Wednesday, December 7, 2022
Muriah Umoquit

Author Q&A: Does treatment for gum disease help people with diabetes control blood sugar levels?

11 months 2 weeks ago

We spoke to Cochrane Oral Health Author Terry Simpson about the updated review Treatment of periodontitis for glycaemic control in people with diabetes mellitus. He explains the results of this review and what it means for the research community as well as medical, nursing, and dental professionals - with thanks also to Josh Twigg, Ambrina Qureshi, Sarah Wild, Ian Needleman and Laura MacDonald.

Terry, can you tell us about this updated Cochrane Review?
Our review of studies evaluating the impact of treatment of periodontitis (gum disease) on glycaemic control in people with diabetes was originally published in 2010 (based on a protocol published in 2004) and first updated in 2015. For the 2022 update, we divided the review in two due to the sheer volume of studies on this topic and to account for the clear divide that has emerged in the research, focusing on two different key questions. This update answers the question: how does treatment of periodontitis compare to usual care or no treatment for improving glycaemic control in people with diabetes; the second part of the update will compare different approaches to treatment of periodontitis against one another, to assess if there is a gold standard for treatment.

This first part of our update found that glycaemic (blood sugar) control in people with diabetes can be improved with treatment of periodontitis. The improvement in diabetic control from treating any periodontitis appears to be approximately equivalent to the threshold for determining effectiveness of an additional diabetes drug - but without the side effects.

What does it mean for the research community?
For the first time since this review began, we have shown that we do not need to conduct further randomised controlled trials that compare periodontal treatment against no treatment or usual care in people who have both diabetes and periodontitis. Within the population of people with diabetes, there is the potential for individuals to improve glycaemic control through treating their periodontitis and therefore we recommend that research should not withhold periodontal treatment from such people for the purpose of a research study that is highly unlikely to add new information to the evidence base. Trials comparing different approaches to periodontal treatment may still be useful, while qualitative studies and process evaluations will be helpful to establish how best to optimise the provision of effective periodontal treatment in primary care settings and to support patients to improve their periodontal health and oral hygiene practices.

Given the evidence is clear, what needs to change?
As treatment of periodontitis in people who also have diabetes can have a beneficial effect on metabolic control (glycaemic levels), it is important that there is better communication between dental and medical professionals managing patients with diabetes and periodontitis as this will facilitate appropriate treatment to minimise risk of complications of diabetes. Unfortunately, care pathways between diabetes and oral health do not exist for most patients. Therefore, healthcare policy and guidance are needed to establish such funded pathways.

For dental professionals, greater awareness is required regarding effective monitoring and treatment of diabetic patients with periodontitis. Professional development for all relevant healthcare staff (including diabetologists, other medical and nursing teams dealing with diabetic patients and the dental professionals) must be delivered to transfer knowledge, address barriers and support implementation. Partnering with organisations that provide information and support for people with diabetes and oral health would be helpful.

Governments may wish to review how socially funded health schemes are addressing the need for periodontal care, particularly among people with diabetes, where the potential for improvement in health and quality of life may be profound. The role of periodontal specialists in providing training and advice on referral for further management is critical in ensuring the dental workforce is equipped to manage this group of patients to the best standard.  

Groups formulating guidelines on diabetes or periodontitis should incorporate the findings of our review so that appropriate educational resources are available for professionals and patients. In the UK, we are aware that NICE have already undertaken this responsibility.

How can clinicians working in this field change what they do?
Medical and nursing professionals should ask all patients diagnosed with diabetes whether they have had a dental visit to get their gums checked and to emphasise the importance of gum health in diabetes management. They can signpost or refer their patients to dental professionals in the case of any unusual presentation or poor oral health identified during general screening on follow-up visits. Similarly, dental professionals (dentists and hygienists/therapists) can advise all patients with diabetes of their increased risk of gum disease and the benefits of good gum health for their overall health and wellbeing. Regular screening of gum health should continue to be provided to all patients, with detailed assessment for those identified at risk of periodontitis. Most patients will continue to be suitable for treatment under the care of a general dentist. However, for people with more severe gum disease and where gum disease is not responding to treatment, referral to a specialist (periodontist) should be considered where available.

Dental and medical professionals can familiarise themselves with the evidence about the links between periodontitis and diabetes. Both professions can assist in the process of educating patients about this relationship. Dentists can play a role in screening for diabetes, considering the possibility of undiagnosed diabetes in patients with risk factors (such as increasing age, higher BMI, non-white ethnicity, family history of diabetes) and the presence of periodontitis, particularly when the condition is severe. They should be able to inform patients of local options for testing for diabetes.

Where can clinicians find out more?

Thursday, June 16, 2022
Lydia Parsonson

World EBHC Day campaign addresses global health challenges through partnerships for purpose

11 months 2 weeks ago

JBI, Cochrane, Campbell, GIN, the Institute for Evidence-Based Healthcare, the Centre for Evidence-based Health Care, and NICE recently launched the World Evidence-Based Healthcare (EBHC) Day 2022 campaign, ‘Partnerships for Purpose’. 

World EBHC Day is held on 20 October each year. It is a global initiative that raises awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally. It is an opportunity to participate in debate about global trends and challenges, but also to celebrate the impact of individuals and organisations worldwide, recognising the work of dedicated researchers, policymakers and health professionals in improving health outcomes.

The 2022 campaign aims to examine partnerships and practical considerations around establishing different types of partnerships, accelerating innovation, ensuring equity and integrity, overcoming challenges and biases, lessons learned and achieving impact for improved health outcomes globally.


There is a growing concern, which was heightened during the pandemic, about making partnerships and collaboration equitable for — and beneficial to — all partners. Although willingness to collaborate has increased, vested interests, bureaucracy and inability to change remain limiting factors. Around the globe, organisations have set up networks, task forces and working groups to coordinate efforts and overcome some of these challenges.

Cochrane’s Editor in Chief, Dr Karla Soares-Weiser says, 

"Partnerships are at the heart of evidence-informed healthcare, and I am very proud of the work Cochrane does with our partners. As a global evidence community, we know that we need to work together to coordinate efforts and make the best use of limited resources. Working together is also an opportunity to listen to and learn from other perspectives, ultimately to benefit the health of all worldwide. I look forward to the discussions that this year’s World EBHC Day campaign on partnerships for purpose will generate."

World EHB Day Events

  • Talking the walk: equity in global health partnerships 
    • 19 October 2022
    • Free webinar
    • In this 90-minute moderated discussion we will hear from key global experts who challenged the status quo of what ‘equity’ means in global health partnerships, including open and engaging conversations with participants.  Includes Tamara Kredo, Deputy Director and Chief Specialist Scientist at Cochrane South Africa. 
  • Making health decisions: what’s best for you?
    • 20 Oct 2022
    • Free webinar
    • Hosted by Cochrane UK, this webinar will equip you with some questions and considerations that you can reflect on and discuss with a healthcare professional – to help you make the best health decision for you.
  • Cochrane and Partnerships
    • 20 Oct 2022
    • Free webinar
    • Hosted by Cochrane US Network, this webinar will focus on why partnerships are important across the spectrum - from your own life to healthcare policy and practice. Come hear from three Cochrane Board members and three Cochrane US mentees.

Cochrane World EBHC Day Blogs

Cochrane World EBHC Day Vlogs


Wednesday, October 19, 2022
Muriah Umoquit
3 hours 48 minutes ago
Subscribe to Cochrane News feed